A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 5, 2023

Primary Completion Date

January 23, 2025

Study Completion Date

January 23, 2025

Conditions

HIV-1-infection

Interventions

BIOLOGICAL

INO-6160, 2 mg

ID EP at month 0,1,3 and 6

BIOLOGICAL

Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)

IM at month 3 and 6

Trial Locations (3)

New York Blood Center CRS, New York

Penn Prevention CRS, Philadelphia

Vanderbuilt Vaccine (VV) CRS, Nashville

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH